Soleo Health opens ambulatory infusion center in Denver area

Soleo Health, a specialty pharmacy company, has opened a new ambulatory infusion site in the Denver area for people with myasthenia gravis (MG) and other diseases requiring infusion therapies. 

The Greenwood Village, Colorado, location offers private infusion sites and is staffed with registered nurses who are experienced in caring for patients with complex, rare or ultra-rare conditions, according to a company press release. It is one of more than 30 infusion sites and centers operated by Soleo throughout the U.S.

“From the moment you step into our Denver infusion center, you’ll experience the respect and understanding you deserve,” the company said on the Denver location’s website. “We recognize the unique challenges you face and strive to make your treatment as comfortable as possible.”

MG is a rare neuromuscular disease characterized by symptoms of muscle weakness and fatigue. For patients with generalized MG (gMG), muscle weakness affects several muscle groups. 

In MG patients, the immune system mistakenly attacks proteins necessary for the proper functioning of the neuromuscular junction, the site where nerve cells and muscles communicate to coordinate voluntary movements. Most MG patients have self-reactive antibodies that target acetylcholine receptors (AChRs), which are normally found on muscle cells.

Recommended Reading

December 16, 2024 Columns by Shawna Barnes

The color teal has meaning in myasthenia gravis — and more

Vygart, Soliris, Ultomiris

Several MG treatments are administered via intravenous, or into-the-vein, infusions. 

In the U.S., Soleo offers infusions of Vyvgart (efgartigimod), an approved gMG treatment that increases the rate at which antibodies, including those that drive MG, are broken down. By lowering the levels of disease-driving antibodies in the blood, the therapy is expected to ease symptoms and reduce disease severity in MG patients who are positive for anti-AChR antibodies.

Patients treated with Vyvgart at a Soleo ambulatory infusion site can expect that Soleo will verify health insurance benefits and obtain prior authorization for treatment. When the first infusion is scheduled, a member of Soleo’s MG therapeutic care management center will contact the patient and assess the person’s condition prior to providing treatment. 

Vyvgart will be administered by a registered nurse, either at a Soleo’s ambulatory infusion center or at the patient’s home. Infusion appointments may take about three hours, including a 60-minute monitoring period following each infusion. 

Patients will be contacted one week and seven weeks after the first infusion for an assessment of the patient’s response to Vyvgart, as well as side effects and overall wellness. This will determine whether the patient should undergo another treatment cycle with Vyvgart.   

Soliris (eculizumab) and Ultomiris (ravulizumab) are also approved therapies for gMG that require intravenous infusions. These therapies work by blocking the complement cascade, a part of the immune system believed to be involved in the autoimmune responses that drive MG. Referrals from a physician are also required for Soleo to dispense either Soliris or Ultomiris. Referral forms can be found on Soleo’s website. The company provides an MG-specific referral form. 

Appointments with flexible times, including weekends, are available at the center, which is near major highways and medical centers, according to the company. The address is 9250 East Costilla Avenue, Suite 440.